Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - sitagliptinum - filmtabletten - sitagliptinum 25 mg ut sitagliptini malas, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso obducto corresp. natrium 0.26 mg. - orales antidiabetikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - sitagliptinum - filmtabletten - sitagliptinum 50 mg ut sitagliptini malas, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 0.52 mg. - orales antidiabetikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - sitagliptinum - filmtabletten - sitagliptinum 100 mg ut sitagliptini malas, cellulosum microcristallinum, calcii hydrogenophosphas, carmellosum natricum conexum, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), e 172 (rubrum), pro compresso obducto corresp. natrium 1.04 mg. - orales antidiabetikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - ezetimibum, simvastatinum - tabletten - ezetimibum 10 mg, simvastatinum 10 mg, lactosum monohydricum 51.631 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, e 300, acidum citricum, e 320, e 310, magnesii stearas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso corresp. natrium 0.5 mg. - reduktion der serumcholesterinkonzentration - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - ezetimibum, simvastatinum - tabletten - ezetimibum 10 mg, simvastatinum 20 mg, lactosum monohydricum 113.262 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, e 300, acidum citricum, e 320, e 310, magnesii stearas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso corresp. natrium 1.1 mg. - reduktion der serumcholesterinkonzentration - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - ezetimibum, simvastatinum - tabletten - ezetimibum 10 mg, simvastatinum 40 mg, lactosum monohydricum 236.524 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, e 300, acidum citricum, e 320, e 310, magnesii stearas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso corresp. natrium 2.2 mg. - reduktion der serumcholesterinkonzentration - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - ezetimibum, simvastatinum - tabletten - ezetimibum 10 mg, simvastatinum 80 mg, lactosum monohydricum 483.048 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, e 300, acidum citricum, e 320, e 310, magnesii stearas, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro compresso corresp. natrium 4.3 mg. - reduktion der serumcholesterinkonzentration - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

tillotts pharma ag - mesalazinum - magensaftresistente tablette - mesalazinum 1600 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 2.268 mg, hypromellosum, silica colloidalis, magnesii stearas, Überzug: hypromellosum, macrogolum 6000, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, triethylis citras, glyceroli monostearas 40-55, polysorbatum 80, kalii dihydrogenophosphas, maydis amylum, e 172, pro compresso obducto. - colitis ulcerosa - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - etanerceptum - injektionslösung im fertigpen - lösung: etanerceptum 25 mg, arginini hydrochloridum, natrii chloridum, saccharum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.55 mg. - rheumatoide arthritis, aktive juvenile idiopatische arthritis (polyarthritis, oligoarthritis, psoriasis-arthritis, enthesitis-assoziierte arthritis), psoriasis-arthritis, bechterew-krankheit (ankylosierende spondylitis), mittelschwere bis schwere plaque-psoriasis - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - kapseln - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika